Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 13, Pages -Publisher
MDPI
DOI: 10.3390/jcm10132834
Keywords
psoriatic arthritis; early arthritis; disease-modifying anti-rheumatic drugs; predictors
Categories
Ask authors/readers for more resources
This retrospective study identified predictors of access to targeted synthetic and biologic disease-modifying anti-rheumatic drugs (ts/bDMARDs) for patients with psoriatic arthritis (PsA). C-reactive protein, Visual Analogue Scale (VAS) pain, and synovial power Doppler (PD) were found to be significant predictors, providing evidence for the need for more intensive monitoring and treatment escalation in early peripheral PsA patients.
With the availability of effective treatment with targeted synthetic and biologic disease-modifying anti-rheumatic drugs (ts/bDMARDs) for psoriatic arthritis (PsA), it is crucial to identify predictors of access to this treatment since disease onset. We retrospectively enrolled patients with peripheral PsA, assessed in an early arthritis clinic from 2005 to 2020. The main baseline demographic, clinical and ultrasonographic (assessment of bilateral wrist and metacarpophalangeal joints) features were evaluated through descriptive statistics and tested as predictors by univariate and multivariate Cox models. The outcome of interest was the indication for ts/bDMARDs within 2 years from diagnosis. We included 238 patients with PsA, with a mean (sd) age of 51.04 (13.98) years; 90 (37.8%) were male, and the median (IQR) symptom duration was 6.12 (3.29-12.25) months. In univariate analyses, C-reactive protein (RR, 95% CI 1.204 (1.065,1.362)), Visual Analogue Scale (VAS) pain (1.027 (1.005,1.048)), the number of tender joints on 28 joints (1.087 (1.025, 1.153)), and a synovial power Doppler (PD) score > 1 (3.63 (1.307, 10.08)) emerged as significant predictors. C-reactive protein, VAS pain and PD confirmed their predictive value also in multivariate models. These results provide preliminary evidence on the features that might characterize patients with early peripheral PsA requiring more intensive monitoring and treatment escalation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available